Search

Your search keyword '"Scaradavou A"' showing total 2,323 results
Start Over Author "Scaradavou A"
2,323 results on '"Scaradavou A"'

2. Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies

Author

Shahid, Sanam, Prockop, Susan E., Flynn, Georgia C., Mauguen, Audrey, White, Charlie O., Bieler, Jennifer, McAvoy, Devin, Hosszu, Kinga, Cancio, Maria I., Jakubowski, Ann A., Scaradavou, Andromachi, Boelens, Jaap Jan, Sauter, Craig S., Perales, Miguel-Angel, Giralt, Sergio A., Taylor, Clare, Chaudhari, Jagrutiben, Wang, Xiuyan, Riviere, Isabelle, Sadelain, Michel, Brentjens, Renier, Kernan, Nancy A., O'Reilly, Richard J., and Curran, Kevin J.

Published
2025
Full Text
View/download PDF

5. Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell–depleted hematopoietic cell transplantation in pediatric and young adult patients

Author

Lakkaraja, Madhavi, Mauguen, Audrey, Boulad, Farid, Cancio, Maria I., Curran, Kevin J., Harris, Andrew C., Kernan, Nancy A., Klein, Elizabeth, Kung, Andrew L., Oved, Joseph, Prockop, Susan, Scaradavou, Andromachi, Spitzer, Barbara, O'Reilly, Richard J., and Boelens, Jaap Jan

Published
2024
Full Text
View/download PDF

6. Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation

Author

Politikos, Ioannis, Brown, Samantha, Fein, Joshua A., Eng, Stephen, Casem, Kristian, Chinapen, Stephanie, Quach, Sean, Scaradavou, Andromachi, Cho, Christina, Dahi, Parastoo, Giralt, Sergio A., Gyurkocza, Boglarka, Hanash, Alan M., Jakubowski, Ann, Papadopoulos, Esperanza B., Perales, Miguel-Angel, Ponce, Doris M., Shaffer, Brian C., Tamari, Roni, Young, James W., Devlin, Sean, Peled, Jonathan U., and Barker, Juliet N.

Published
2024
Full Text
View/download PDF

7. Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant

Author

Fabrizio, Vanessa A, Kernan, Nancy A, Boulad, Farid, Cancio, Maria, Allen, Jennifer, Higman, Meghan, Margossian, Steven P, Mauguen, Audrey, Prockop, Susan, Scaradavou, Andromachi, Shah, Niketa, Spitzer, Barbara, Stieglitz, Elliot, Yeager, Nicholas, O’Reilly, Richard J, Brentjens, Renier J, Jan Boelens, Jaap, and Curran, Kevin J

Subjects
Stem Cell Research - Nonembryonic - Human, Pediatric, Stem Cell Research, Clinical Research, Transplantation, Cancer, Clinical Trials and Supportive Activities, Regenerative Medicine, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Child, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunotherapy, Adoptive, Infant, Neoplasm Recurrence, Local, Retrospective Studies, T-Lymphocytes, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Immunology
Abstract

To define the tolerability and outcome of allogeneic hematopoietic stem cell transplant (allo-HSCT) following CAR T-cell therapy, we retrospectively reviewed pediatric/young adult patients with relapsed/refractory B-ALL who underwent this treatment. Fifteen patients (median age 13 years; range 1-20 years) with a median potential follow-up of 39 months demonstrated 24-month cumulative incidence of relapse, cumulative incidence of TRM, and OS of 16% (95% CI: 0-37%), 20% (95% CI: 0-40%), and 80% (95% CI: 60-100%), respectively. Severe toxicity following CAR T cells did not impact OS (p = 0.27), while greater time from CAR T cells to allo-HSCT (>80 days) was associated with a decrease in OS. In comparing CD34-selected T-cell depleted (TCD; n = 9) vs unmodified (n = 6) allo-HSCT, the cumulative incidence of relapse, TRM, and OS at 24 months was 22% (95% CI: 0-49%) vs 0% (p = 0.14), 0% vs 50% [95% CI: 10-90%] (p = 0.02) and 100% vs 50% [95% CI: 10-90%] (p = 0.02). In this small cohort of patients, CAR T cells followed by a CD34-selected TCD allo-HSCT appears to result in less TRM and favorable OS when compared with unmodified allo-HSCT. There was no evidence that disease control was impacted by the type of consolidative allo-HSCT, which demonstrates the feasibility of this approach.

Published
2020

8. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation

Author

Tamari, Roni, Scordo, Michael, Kunvarjee, Binni M., Proli, Anthony, Lin, Andrew, Flynn, Jessica, Cho, Christina, Devlin, Sean, Klein, Elizabeth, Boulad, Farid, Cancio, Maria I., Curran, Kevin J., Jakubowski, Ann A., Kernan, Nancy A., Kung, Andrew L., O’Reilly, Richard J., Papadopoulos, Esperanza B., Prockop, Susan, Scaradavou, Andromachi, Shaffer, Brian C., Shah, Gunjan, Spitzer, Barbara, Gyurkocza, Boglarka, Giralt, Sergio A., Perales, Miguel-Angel, and Boelens, Jaap Jan

Published
2023
Full Text
View/download PDF

9. Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia

Author

Fingrut, Warren B., Gyurkocza, Boglarka, Flynn, Jessica, Davis, Eric, Devlin, Sean, Scaradavou, Andromachi, Chinapen, Stephanie, Quach, Sean, Cho, Christina, Giralt, Sergio A., Jakubowski, Ann A., Lin, Richard J., Papadopoulos, Esperanza B., Perales, Miguel-Angel, Ponce, Doris, Shaffer, Brian C., Tamari, Roni, Young, James W., Politikos, Ioannis, and Barker, Juliet N.

Published
2023
Full Text
View/download PDF

10. Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients

Author

Alexandre G. Troullioud Lucas, Jaap Jan Boelens, Susan E. Prockop, Kevin J. Curran, Dorine Bresters, Wouter Kollen, Birgitta Versluys, Marc B. Bierings, Anne Archer, Eric Davis, Elizabeth Klein, Nancy A. Kernan, Caroline A. Lindemans, and Andromachi Scaradavou

Subjects
cord blood transplant, relapse, second transplant, leukemia, treatment related mortality, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

BackgroundPatients with leukemia relapse after allogeneic hematopoietic cell transplant (HCT) have poor survival due to toxicity and disease progression. A second HCT often offers the only curative treatment.MethodsWe retrospectively reviewed our bi-institutional experience (MSKCC-USA; Utrecht-NL) with unrelated cord blood transplantation (CBT) for treatment of post-transplant relapse. Overall survival (OS) and event-free survival (EFS) were evaluated using the Kaplan-Meier method, treatment-related mortality (TRM) and relapse were evaluated using the competing risk method by Fine-Gray.ResultsTwenty-six patients age < 21 years received a second (n=24) or third (n=2) HCT with CB grafts during the period 2009-2021. Median age at first HCT (HCT1) was 11.5 (range: 0.9-17.7) years and all patients received myeloablative cytoreduction. Median time from HCT1 to relapse was 12.8 (range 5.5-189) months. At CBT, median patient age was 13.5 (range 1.4-19.1) years. Diagnoses were AML: 13; ALL: 4, MDS: 5, JMML: 2; CML: 1; mixed phenotype acute leukemia: 1. Sixteen patients (62%) were in advanced stage, either CR>2 or with active disease. Median time from HCT1 to CBT was 22.2 (range 7-63.2) months. All patients engrafted after CBT. Thirteen patients developed acute GvHD; 7 had grade III or IV. With a median survivor follow-up of 46.6 (range 17.4-155) months, 3-year OS was 69.2% (95% CI 53.6-89.5%) and 3-year EFS was 64.9% (95% CI 48.8-86.4%). Eight patients died, 3 of AML relapse and 5 due to toxicity (respiratory failure [n=4], GvHD [n=1]) at a median time of 7.7 (range 5.9-14.4) months after CBT. Cumulative incidence of TRM at 3 years was 19.2% (95% CI 4.1-34.4%). Notably, all TRM events occurred in patients transplanted up to 2015; no toxicity-related deaths were seen in the 16 patients who received CBT after 2015. Cumulative incidence of relapse was 15.9% (95% CI 1.6-30.2%) at 3 years, remarkably low for these very high-risk patients.ConclusionsSurvival was very encouraging following CB transplants in pediatric patients with recurrent leukemia after first HCT, and TRM has been low over the last decade. CBT needs to be strongly considered as a relatively safe salvage therapy option for post-transplant relapse.

Published
2023
Full Text
View/download PDF

11. Persistent or New Cytopenias Predict Relapse Better than Routine Bone Marrow Aspirate Evaluations After Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome in Children and Young Adult Patients

Author

Kernan, Nancy A., Klein, Elizabeth, Mauguen, Audrey, Torok-Castanza, Joanne, Prockop, Susan E., Scaradavou, Andromachi, Curran, Kevin, Spitzer, Barbara, Cancio, Maria, Ruggiero, Julianne, Allen, Jennifer, Harris, Andrew, Oved, Joseph, O'Reilly, Richard J., and Boelens, Jaap Jan

Published
2024
Full Text
View/download PDF

12. Antithymocyte globulin exposure in CD34+ T-cell–depleted allogeneic hematopoietic cell transplantation

Author

Lakkaraja, Madhavi, Scordo, Michael, Mauguen, Audrey, Cho, Christina, Devlin, Sean, Ruiz, Josel D., Klein, Elizabeth, Avecilla, Scott T., Boulad, Farid, Cancio, Maria I., Curran, Kevin J., Jakubowski, Ann A., Kernan, Nancy A., Kung, Andrew L., O'Reilly, Richard J., Papadopoulos, Esperanza B., Prockop, Susan, van Roessel, Ichelle, Scaradavou, Andromachi, Shaffer, Brian C., Shah, Gunjan, Spitzer, Barbara, Tamari, Roni, Giralt, Sergio A., Perales, Miguel-Angel, and Boelens, Jaap Jan

Published
2022
Full Text
View/download PDF

13. CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation

Author

de Koning, Coco, Prockop, Susan, van Roessel, Ichelle, Kernan, Nancy, Klein, Elizabeth, Langenhorst, Jurgen, Szanto, Celina, Belderbos, Mirjam, Bierings, Marc, Boulad, Farid, Bresters, Dorine, Cancio, Maria, Curran, Kevin, Kollen, Wouter, O'Reilly, Richard, Scaradavou, Andromachi, Spitzer, Barbara, Versluijs, Birgitta, Huitema, Alwin, Lindemans, Caroline, Nierkens, Stefan, and Boelens, Jaap Jan

Published
2021
Full Text
View/download PDF

14. High progression-free survival after intermediate intensity double unit cord blood transplantation in adults

Author

Barker, Juliet N., Devlin, Sean M., Naputo, Kristine A., Skinner, Kelcey, Maloy, Molly A., Flynn, Lisa, Anagnostou, Theodora, Avecilla, Scott T., Scaradavou, Andromachi, Cho, Christina, Dahi, Parastoo B., Giralt, Sergio A., Gyurkocza, Boglarka, Hanash, Alan M., Hsu, Katharine, Jakubowski, Ann A., Papadopoulos, Esperanza B., Peled, Jonathan U., Perales, Miguel-Angel, Sauter, Craig S., Shah, Gunjan L., Shaffer, Brian C., Tamari, Roni, Young, James W., Roshal, Mikhail, O'Reilly, Richard J., Ponce, Doris M., and Politikos, Ioannis

Published
2020
Full Text
View/download PDF

15. Guidelines for Cord Blood Unit Selection

Author

Politikos, Ioannis, Davis, Eric, Nhaissi, Melissa, Wagner, John E., Brunstein, Claudio G., Cohen, Sandra, Shpall, Elizabeth J., Milano, Filippo, Scaradavou, Andromachi, and Barker, Juliet N.

Published
2020
Full Text
View/download PDF

16. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response

Author

Chaekal, Ok-kyong, Scaradavou, Andromachi, Masson Frenet, Emeline, Albano, Maria S., Cushing, Melissa, Desai, Pinkal, Dobrila, Ludy, Gergis, Usama, Guarneri, Danielle, Hsu, Jing-Mei, Lee, Sangmin, Mayer, Sebastian A., Phillips, Adrienne A., Orfali, Nina, Ritchie, Ellen K., Roboz, Gail J., Romeo, Cynthia, Samuel, Michael S., Shore, Tsiporah, and van Besien, Koen

Published
2020
Full Text
View/download PDF

20. Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients

Author

Ballen, Karen, Logan, Brent R., Chitphakdithai, Pintip, Kuxhausen, Michelle, Spellman, Stephen R., Adams, Alexia, Drexler, Rebecca J., Duffy, Merry, Kemp, Ann, King, Roberta, Babic, Aleksandar, Delaney, Colleen, Karanes, Chatchada, Kurtzberg, Joanne, Petz, Lawrence, Scaradavou, Andromachi, Shpall, Elizabeth J., Smith, Clayton, Confer, Dennis L., and Miller, John P.

Published
2020
Full Text
View/download PDF

21. NAVIGATING LYMPHOCYTE RECONSTITUTION: INSIGHTS INTO AGVHD PHASES

Author

Mcavoy, D., primary, Hosszu, K., additional, Vidal, E.H., additional, Singh, K.H., additional, Thomsen, M., additional, Ntrivalas, E., additional, Klein, E., additional, Lucas, A. Troullioud, additional, Harris, A., additional, Curran, K.J., additional, Cancio, M., additional, Alsultan, A., additional, Scaradavou, A., additional, Oved, J., additional, Perales, M., additional, Kung, A., additional, and Boelens, J.J., additional

Published
2024
Full Text
View/download PDF

22. Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation

Author

Major-Monfried, Hannah, primary, Hosszu, Kinga, additional, McAvoy, Devin P., additional, Vallone, Alexander, additional, Shukla, Neerav, additional, Gillio, Alfred, additional, Spitzer, Barbara, additional, Kung, Andrew L., additional, Cancio, Maria, additional, Curran, Kevin, additional, Scaradavou, Andromachi, additional, Oved, Joseph H., additional, O'Reilly, Richard J., additional, Boelens, Jaap Jan, additional, and Harris, Andrew C., additional

Published
2024
Full Text
View/download PDF

27. Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin

Author

Politikos, Ioannis, Devlin, Sean M., Arcila, Maria E., Barone, Jonathan C., Maloy, Molly A., Naputo, Kristine A., Ruiz, Josel D., Mazis, Christopher M., Scaradavou, Andromachi, Avecilla, Scott T., Dahi, Parastoo B., Giralt, Sergio A., Hsu, Katherine C., Jakubowski, Ann A., Papadopoulos, Esperanza B., Perales, Miguel A., Sauter, Craig S., Tamari, Roni, Ponce, Doris M., O’Reilly, Richard J., and Barker, Juliet N.

Published
2021
Full Text
View/download PDF

30. Racial/ ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation

Author

Fingrut, Warren B, primary, Davis, Eric, additional, Archer, Anne, additional, Brown, Samantha, additional, Devlin, Sean M., additional, Nhaissi, Melissa, additional, Rapoport, Candice, additional, Chinapen, Stephanie, additional, Kelly, Amanda, additional, Wells, Deborah S, additional, Scaradavou, Andromachi, additional, Gyurkocza, Boglarka, additional, Papadopoulos, Esperanza B., additional, Politikos, Ioannis, additional, Shaffer, Brian C, additional, and Barker, Juliet, additional

Published
2024
Full Text
View/download PDF

32. Regulatory T Cell Reconstitution Is Associated with Acute Graft-Versus-Host Disease in Pediatric and Young Adult Hematopoietic Cell Transplant Recipients

Author

Hosszu, Kinga, primary, McAvoy, Devin, additional, Garcia-Rosa, Moises, additional, White, Charlie, additional, Thomsen, Matthew, additional, Ntrivalas, Evangelos, additional, Klein, Elizabeth, additional, Mauguen, Audrey, additional, Curran, Kevin J., additional, Cancio, Maria I., additional, Scaradavou, Andromachi, additional, Kung, Andrew L., additional, Oved, Joseph H., additional, Perales, Miguel-Angel, additional, Harris, Andrew C., additional, and Boelens, Jaap Jan, additional

Published
2024
Full Text
View/download PDF

33. High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

Author

Politikos, Ioannis, primary, Brown, Samantha, additional, Fingrut, Warren Benjamin, additional, Chinapen, Ms. Stephanie, additional, Quach, Sean, additional, Dahi, Parastoo B., additional, Gyurkocza, Boglarka, additional, Jakubowski, Ann A., additional, Papadopoulos, Esperanza B., additional, Perales, Miguel-Angel, additional, Ponce, Doris M., additional, Tamari, Roni, additional, Scaradavou, Andromachi, additional, and Barker, Juliet, additional

Published
2024
Full Text
View/download PDF

34. Model-Based Dosing of Anti-Thymocyte Globulin in Pediatric Allogeneic Hematopoietic Cell Transplantation Improves Survival Chances: Updated Results from the Single Arm Phase II Parachute-Trial Combined with Real-World Data

Author

Admiraal, Rick, primary, Nierkens, Stefan, additional, Bierings, Marc, additional, Belderbos, Mirjam, additional, Huitema, Alwin D.R., additional, Bredius, Robbert, additional, Jiang, Yilin, additional, Curran, Kevin J., additional, Harris, Andrew C., additional, Scaradavou, Andromachi, additional, Cancio, Maria I., additional, Klein, Elizabeth, additional, Kollen, Wouter, additional, Bresters, Dorine, additional, Calkoen, Friso, additional, Versluijs, A. Birgitta, additional, Zwaan, Christian M., additional, Boelens, Jaap-Jan, additional, and Lindemans, Caroline A., additional

Published
2024
Full Text
View/download PDF

35. Real-World Analysis of 3,843 Unrelated Donors (URDs) for 455 Allograft Candidates Reveals Low URD Availability with Marked Racial/ Ethnic Disparities: Implications for Transplant Center & Registry Operations

Author

Fingrut, Warren Benjamin, primary, Davis, Eric, additional, Archer, Anne, additional, Brown, Samantha, additional, Devlin, Sean M., additional, Nhaissi, Melissa, additional, Rapoport, Candice, additional, Chinapen, Ms. Stephanie, additional, Kelly, Amanda, additional, Wells, Deborah S., additional, Scaradavou, Andromachi, additional, Gyurkocza, Boglarka, additional, Papadopoulos, Esperanza B., additional, Politikos, Ioannis, additional, Shaffer, Brian C., additional, and Barker, Juliet, additional

Published
2024
Full Text
View/download PDF

36. Predictors for Recent Thymic Emigrant T Cell Reconstitution after Hematopoietic Cell Transplantation

Author

McAvoy, Devin, primary, Hosszu, Kinga, additional, Vidal, Esther Hadassa, additional, Singh, Katina H, additional, Thomsen, Matthew, additional, Ntrivalas, Evangelos, additional, Klein, Elizabeth, additional, Harris, Andrew C., additional, Curran, Kevin J., additional, Cancio, Maria I., additional, Scaradavou, Andromachi, additional, Oved, Joseph H., additional, Kung, Andrew L., additional, and Boelens, Jaap Jan, additional

Published
2024
Full Text
View/download PDF

37. Early CD4 and B Cell Immune Reconstitution As Predictors of Outcomes in T Cell Depleted Allogeneic Hematopoietic Cell Transplantation

Author

Lucas, Alexandre G. Troullioud, primary, Scordo, Michael, additional, Lakkaraja, Madhavi, additional, Cho, Christina, additional, Jakubowski, Ann A., additional, Papadopoulos, Esperanza B., additional, Tamari, Roni, additional, Curran, Kevin J., additional, O'Reilly, Richard J., additional, Scaradavou, Andromachi, additional, Gyurkocza, Boglarka, additional, Giralt, Sergio A., additional, Perales, Miguel-Angel, additional, and Boelens, Jaap Jan, additional

Published
2024
Full Text
View/download PDF

38. Gender Disparities in Allograft Access Due to HLA-Sensitization in Multiparous Women:Implications for Evaluation of Female Patients for Alternative Donor Transplantation

Author

Fingrut, Warren Benjamin, primary, Davis, Eric, additional, Archer, Anne, additional, Brown, Samantha, additional, Devlin, Sean M., additional, Chinapen, Ms. Stephanie, additional, Scaradavou, Andromachi, additional, Politikos, Ioannis, additional, Blouin, Amanda G, additional, Shaffer, Brian C., additional, and Barker, Juliet, additional

Published
2024
Full Text
View/download PDF

39. Combined umbilical cord blood and bone marrow from HLA‐identical sibling donors for hematopoietic stem cell transplantation in children with hemoglobinopathies

Author

Soni, Sandeep, Boulad, Farid, Cowan, Morton J, Scaradavou, Andromachi, Dahake, Jueeli, Edwards, Sandie, and Walters, Mark C

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Stem Cell Research - Umbilical Cord Blood/ Placenta, Stem Cell Research - Nonembryonic - Human, Clinical Research, Transplantation, Hematology, Stem Cell Research, Regenerative Medicine, Stem Cell Research - Nonembryonic - Non-Human, Pediatric, Stem Cell Research - Umbilical Cord Blood/ Placenta - Human, 5.2 Cellular and gene therapies, Development of treatments and therapeutic interventions, Good Health and Well Being, Adolescent, Bone Marrow Transplantation, Child, Child, Preschool, Cord Blood Stem Cell Transplantation, Feasibility Studies, Female, Follow-Up Studies, Graft Survival, HLA Antigens, Hematopoietic Stem Cell Transplantation, Hemoglobinopathies, Histocompatibility Testing, Humans, Infant, Male, Prognosis, Survival Rate, bone marrow transplant, cord blood transplant, hemoglobinopathy, sickle cell disease, thalassemia, Clinical Sciences, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Oncology and carcinogenesis, Paediatrics
Abstract

BackgroundIt is well established that umbilical cord blood and bone marrow are biologically different stem cell sources.Patients and methodsWe analyzed the feasibility and outcome of hematopoietic stem cell transplantation (HSCT) in 13 children (median age 5.9 years) with hemoglobinopathies after the co- infusion of cord blood (CB) and bone marrow (BM) from the same human leucocyte antigen (HLA) identical sibling donor. We also compared outcomes of children with co-transplantation to outcomes in children with hemoglobinopathies who had received a BM (n = 21) or CB (n = 22) transplant alone.ResultsCompared to CB transplant (CBT) recipients, the co-transplant group had more rapid neutrophil (17 vs. 25 days, P = 0.013) and platelet (29 vs. 48 days, P = 0.009) recovery and less transplant related mortality. Patients who received a co-transplant had a lower incidence of ≥ grade II acute (0% vs. 26.3%) and chronic (0% vs. 21%) graft versus host disease (GVHD) compared to BM transplant (BMT) recipients (P = 0.055 and 0.045, respectively). With a median follow-up of >60 months in each treatment group, the 5-year probability of event free survival (EFS) was 100% in the co-transplant group, 90% after BMT and 86% after CBT (P = 0.42).ConclusionCo-transplantation of CB and BM from HLA-identical sibling donors appears to be a feasible and effective strategy to further optimize outcomes of HSCT for hemoglobinopathies.

Published
2014

40. Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes

Author

Gergis, Usama, Frenet, Emeline Masson, Shore, Tsiporah, Mayer, Sebastian, Phillips, Adrienne, Hsu, Jing-Mei, Roboz, Gail, Ritchie, Ellen, Scandura, Joseph, Lee, Sangmin, Desai, Pinkal, Samuel, Michael, Ball, Jeffrey, Blanco, Anthony, Romeo, Cynthia, Albano, Maria S., Dobrila, Ludy, Scaradavou, Andromachi, and van Besien, Koen

Published
2019
Full Text
View/download PDF

46. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies

Author

Spitzer, Barbara, Jakubowski, Ann A., Papadopoulos, Esperanza B., Fuller, Kirsten, Hilden, Patrick D., Young, James W., Barker, Juliet N., Koehne, Guenther, Perales, Miguel-Angel, Hsu, Katharine C., van den Brink, Marcel R., Kernan, Nancy A., Prockop, Susan E., Scaradavou, Andromachi, Castro-Malaspina, Hugo, O'Reilly, Richard J., and Boulad, Farid

Published
2017
Full Text
View/download PDF

47. Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection

Author

Kosuri, Satyajit, Wolff, Tara, Devlin, Sean M., Byam, Courtney, Mazis, Christopher M., Naputo, Kristine, Davis, Eric, Paulson, Jennifer, Nhaissi, Melissa, Wells, Deborah S., Dahi, Parastoo, Giralt, Sergio A., Jakubowski, Ann, Perales, Miguel-Angel, Shaffer, Brian C., Scaradavou, Andromachi, Ponce, Doris M., and Barker, Juliet N.

Published
2017
Full Text
View/download PDF

49. Donor‐specific antibody desensitization with daratumumab prior to haematopoietic cell transplant for sickle cell disease: A case report.

Author

Kunvarjee, Binni, Contreras Yametti, Gloria Paz, Blouin, Amanda G., Linder, Grace E., Borge, P. Dayand, Maryamchik, Elena, Budhai, Alexandra, Gupta, Gaurav K., Scaradavou, Andromachi, Spitzer, Barbara G., Curran, Kevin J., Oved, Joseph H., Harris, Andrew C., Sharma, Akshay, Boelens, Jaap Jan, and Cancio, Maria I.

Subjects
SICKLE cell anemia, DARATUMUMAB, AUTOIMMUNE hemolytic anemia, PURE red cell aplasia, HEMATOPOIETIC stem cell transplantation
Abstract

This article discusses a case report of a patient with sickle cell disease (SCD) who underwent a donor-specific antibody desensitization treatment using daratumumab prior to a hematopoietic cell transplant. The patient had a history of red cell antibodies and high levels of HLA antibodies, which increased the risk of graft failure. Traditional pretransplant immune suppression methods were ineffective, so the patient received daratumumab along with other treatments, resulting in a reduction in antibody levels. The patient successfully underwent the transplant and achieved full donor chimerism with no evidence of graft-versus-host disease. This is the first reported use of daratumumab for this indication in SCD. The document also includes a table summarizing three different studies on patients who underwent allogeneic hematopoietic cell transplantation (AlloHCT), providing information on various factors such as desensitization regimens and donor chimerism. The authors acknowledge funding support and declare any conflicts of interest. [Extracted from the article]

Published
2024
Full Text
View/download PDF

50. Racial disparities in access to alternative donor allografts persist in the era of 'donors for all'

Author

Warren B. Fingrut, Boglarka Gyurkocza, Eric Davis, Jessica Flynn, Stephanie Chinapen, Kristine A. Naputo, Sean Quach, Christina Cho, Sergio A. Giralt, Ann A. Jakubowski, Richard J. Lin, Esperanza Papadopoulos, Miguel-Angel Perales, Doris M. Ponce, Brian C. Shaffer, Craig S. Sauter, Roni Tamari, James W. Young, Andromachi Scaradavou, Ioannis Politikos, and Juliet N. Barker

Subjects
Humans, Transplantation, Homologous, Hematology, Healthcare Disparities, Allografts, Tissue Donors
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results